How Two Enzymes Hijack NAD Metabolism to Drive Cancer Resistance
NAMPT and NNMT coordinate nicotinamide metabolism to rewire cancer cell epigenetics and immune evasion — revealing new combination therapy targets.
Summary
Cancer cells are remarkably adaptable, and a new review explains a key reason why: two enzymes, NAMPT and NNMT, work in tandem to control how cells use nicotinamide — the building block of NAD+. NAMPT keeps intracellular NAD+ levels high, fueling energy production, DNA repair, and stress responses. NNMT diverts nicotinamide away from NAD+ synthesis and instead uses it to drain methyl groups, reshaping gene expression in ways that make tumors more plastic and harder to treat. Both enzymes also act outside the cell, influencing the tumor microenvironment, stromal remodeling, and immune evasion. Together they form a metabolic-epigenetic-immune network that helps tumors adapt to therapy. The review proposes targeting both enzymes simultaneously as a context-dependent strategy to overcome cancer resistance.
Detailed Summary
NAD+ is one of the most studied molecules in longevity science, yet cancer biology reveals a darker side of nicotinamide metabolism. This review from researchers at the University of Eastern Piedmont lays out how two nicotinamide-metabolizing enzymes — NAMPT and NNMT — act as complementary master regulators that cancer cells exploit to survive, adapt, and resist treatment.
NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway. By maintaining high intracellular NAD+ pools, it sustains mitochondrial function, redox homeostasis, DNA repair, and stress responses — essentially keeping cancer cells energetically robust under harsh conditions. NNMT plays the opposite role intracellularly: it methylates nicotinamide using S-adenosylmethionine (SAM), diverting it away from NAD+ biosynthesis and creating what the authors call a 'methylation sink.' This depletion of SAM remodels chromatin and increases transcriptional plasticity, giving tumors epigenetic flexibility to adapt their gene expression programs.
Beyond the cell, both enzymes have extracellular functions. Extracellular NAMPT (eNAMPT) acts as a cytokine-like signal regulating immune cell behavior and promoting chronic inflammation. The extracellular form of NNMT and its metabolite 1-methylnicotinamide (1-MNA) modulate stromal remodeling and immune evasion, helping tumors suppress anti-tumor immunity.
The review proposes a unified conceptual model in which NAMPT and NNMT function across interconnected intracellular and extracellular levels, integrating metabolic, epigenetic, and immunometabolic signals to drive tumor progression and therapeutic resistance. This framework points toward combination therapies that simultaneously target both enzymes in a context-dependent manner.
For longevity researchers, this work matters because NAD+ precursors like NMN and NR are widely used supplements — and understanding how cancer cells exploit the same pathway raises important questions about context-specific effects of NAD+ boosting in oncology settings.
Key Findings
- NAMPT sustains NAD+ pools in cancer cells, supporting energy production, DNA repair, and stress resistance.
- NNMT creates a methylation sink by consuming SAM, remodeling chromatin and increasing tumor transcriptional plasticity.
- Extracellular NAMPT and NNMT regulate immune evasion and stromal remodeling in the tumor microenvironment.
- NAMPT and NNMT together form a multilevel metabolic-epigenetic-immune network driving therapy resistance.
- Simultaneous targeting of both enzymes is proposed as a context-dependent combination cancer therapy strategy.
Methodology
This is a narrative review article published in Cancer Letters, synthesizing existing literature on NAMPT and NNMT biology in cancer. The authors develop a conceptual framework integrating metabolic, epigenetic, and immunological findings from prior studies. No original experimental data were generated for this review.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. As a narrative review, the framework is conceptual and has not been validated in prospective clinical studies. The clinical translatability of dual NAMPT/NNMT inhibition requires further experimental and trial-based evidence.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: